516 related articles for article (PubMed ID: 33001273)
1. Assessment of acute kidney injury related to small-molecule protein kinase inhibitors using the FDA adverse event reporting system.
Fan Q; Ma J; Zhang B; Li Q; Liu F; Zhao B
Cancer Chemother Pharmacol; 2020 Nov; 86(5):655-662. PubMed ID: 33001273
[TBL] [Abstract][Full Text] [Related]
2. Drug-Associated Acute Kidney Injury Identified in the United States Food and Drug Administration Adverse Event Reporting System Database.
Welch HK; Kellum JA; Kane-Gill SL
Pharmacotherapy; 2018 Aug; 38(8):785-793. PubMed ID: 29883524
[TBL] [Abstract][Full Text] [Related]
3. Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).
Patek TM; Teng C; Kennedy KE; Alvarez CA; Frei CR
Drug Saf; 2020 Jan; 43(1):17-22. PubMed ID: 31691256
[TBL] [Abstract][Full Text] [Related]
4. Surveillance of drugs that most frequently induce acute kidney injury: A pharmacovigilance approach.
Hosohata K; Inada A; Oyama S; Furushima D; Yamada H; Iwanaga K
J Clin Pharm Ther; 2019 Feb; 44(1):49-53. PubMed ID: 30014591
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors associated acute kidney injury and chronic kidney disease: data mining of US FDA adverse event reporting system.
Wu B; Li D; Xu T; Luo M; He Z; Li Y
Sci Rep; 2021 Feb; 11(1):3690. PubMed ID: 33574396
[TBL] [Abstract][Full Text] [Related]
6. Pleural adverse drugs reactions and protein kinase inhibitors: Identification of suspicious targets by disproportionality analysis from VigiBase.
Mahé J; de Campaigno EP; Chené AL; Montastruc JL; Despas F; Jolliet P
Br J Clin Pharmacol; 2018 Oct; 84(10):2373-2383. PubMed ID: 29943846
[TBL] [Abstract][Full Text] [Related]
7. Thromboembolic events associated with immune checkpoint inhibitors: A real-world study of data from the food and drug administration adverse event reporting system (FAERS) database.
Li H; Sun X; Sun D; Zhao J; Xu Z; Zhao P; Ma Z; Zhang Y
Int Immunopharmacol; 2021 Sep; 98():107818. PubMed ID: 34130149
[TBL] [Abstract][Full Text] [Related]
8. Acute kidney injury following the use of different proton pump inhibitor regimens: A real-world analysis of post-marketing surveillance data.
Chen G; Ning LJ; Qin Y; Zhao B; Mei D; Li XM
J Gastroenterol Hepatol; 2021 Jan; 36(1):156-162. PubMed ID: 32542684
[TBL] [Abstract][Full Text] [Related]
9. DPP-4 Inhibitors and Increased Reporting Odds of Bullous Pemphigoid: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS) from 2006 to 2020.
Jedlowski PM; Jedlowski MF; Fazel MT
Am J Clin Dermatol; 2021 Nov; 22(6):891-900. PubMed ID: 34287770
[TBL] [Abstract][Full Text] [Related]
10. A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib.
Peng L; Xiao K; Ottaviani S; Stebbing J; Wang YJ
Expert Opin Drug Saf; 2020 Nov; 19(11):1505-1511. PubMed ID: 32693646
[TBL] [Abstract][Full Text] [Related]
11. Acute kidney injury associated with immune checkpoint inhibitors: A pharmacovigilance study.
Zhu J; Wu J; Chen P; You K; Su J; Gao Z; Bi Z; Feng M
Int Immunopharmacol; 2022 Dec; 113(Pt A):109350. PubMed ID: 36272360
[TBL] [Abstract][Full Text] [Related]
12. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
13. Fluid retention-associated adverse events in patients treated with BCR::ABL1 inhibitors based on FDA Adverse Event Reporting System (FAERS): a retrospective pharmacovigilance study.
Huang J; Cai J; Ye Q; Jiang Q; Lin H; Wu L
BMJ Open; 2023 Aug; 13(8):e071456. PubMed ID: 37536976
[TBL] [Abstract][Full Text] [Related]
14. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
15. Antibacterial-associated acute kidney injury among older adults: A post-marketing surveillance study using the FDA adverse events reporting system.
Chinzowu T; Chyou TY; Nishtala PS
Pharmacoepidemiol Drug Saf; 2022 Nov; 31(11):1190-1198. PubMed ID: 35670078
[TBL] [Abstract][Full Text] [Related]
16. A real-world pharmacovigilance study of amivantamab-related cardiovascular adverse events based on the FDA adverse event reporting system (FAERS) database.
Sun R; Ning Z; Qin H; Zhang W; Teng Y; Jin C; Liu J; Wang A
Sci Rep; 2024 Apr; 14(1):9552. PubMed ID: 38664423
[TBL] [Abstract][Full Text] [Related]
17. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
18. Acute kidney injury following SGLT2 inhibitors among diabetic patients: a pharmacovigilance study.
Chen G; Li X; Cui Q; Zhou Y; Zhao B; Mei D; Xuemei
Int Urol Nephrol; 2022 Nov; 54(11):2949-2957. PubMed ID: 35579781
[TBL] [Abstract][Full Text] [Related]
19. Immune-related adverse events of immune checkpoint inhibitors combined with angiogenesis inhibitors: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database (2014-2022).
Ren X; Wang H; Deng L; Wang W; Wang Y
Int Immunopharmacol; 2024 Jul; 136():112301. PubMed ID: 38838553
[TBL] [Abstract][Full Text] [Related]
20. Association between Concomitant Use of Acyclovir or Valacyclovir with NSAIDs and an Increased Risk of Acute Kidney Injury: Data Mining of FDA Adverse Event Reporting System.
Yue Z; Shi J; Li H; Li H
Biol Pharm Bull; 2018 Feb; 41(2):158-162. PubMed ID: 29187701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
